Abstract
Daridorexant belongs to a class of drugs known as dual orexin receptor (OX1R and OX2R) antagonists. It achieves its function by blocking the binding of wake-promoting neuropeptides orexins. This novel mechanism is believed to turn down overactive wakefulness and as we know so far, most other treatments for insomnia can be sedating.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.